Research Details
- Funding Organization : European Commission
- Funding Programme : HP-JA-2016
- Funding Instrument : Joint Action
- Duration : 36 months
- Total Budget : 1,999,877 EUR
- ITI Budget : 170,472 EUR
- Scientific Responsible : Dr. Dimitrios Tzovaras
Description
The “Joint Action on integrating prevention, testing and link to care strategies across HIV, Viral Hepatitis, TB & STIs in Europe” (INTEGRATE) has the overall objective to increase Integrated early diagnosis and linkage to prevention and care of HIV, viral hepatitis, TB and STIs in EU Member States by 2020.
A number of tools have been developed to reduce transmission, optimize early diagnosis and linkage to care for one or more of these four diseases. INTEGRATE will map relevant existing tools for cross-linking. A peer-review process will identify which of these tools are complimentary or redundant for other disease(s), and which could be adapted or require further innovation. HIV, viral hepatitis, TB and STIs are cross-borders public health threats of concern to Europe that affect vulnerable populations disproportionately and require personalised interventions. As multiple dimensional approaches are required to reduce the public health burden, the most optimal profile of approaches that provide additive effects (and that are reasonably cost-effective) should be identified and implemented broadly.
INTEGRATE provides a platform to disseminate and exchange best practice among Member States and facilitate discussions on innovations and emerging issues within the four diseases. In this respect, INTEGRATE is a shared European effort that extends beyond the partners and can create important synergies across European stakeholders, projects and initiatives.
INTEGRATE supports the implementation of the Commission Communication on ‘Combating HIV/AIDS in the European Union and neighboring countries’ and the ‘Action Plan on HIV/AIDS in the EU and neighboring countries’ by ensuring better preparedness across the EU and by identifying innovative evidence-based testing and prevention tools to reduce new cases of HIV, viral hepatitis, TB and STIs in priority groups.
Consortium
- REGION HOVEDSTADEN (REGIONH) – Denmark
- ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS (CERTH) – Greece
- TERVISE ARENGU INSTITUUT (TAI) – Estonia
- INSTITUT CATALA D’ONCOLOGIA (ICO) – Spain
- NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ) – Slovenia
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (UCD) – Ireland
- FONDAZIONE LEGA ITALIANA PER LA LOTTA CONTRO L’AIDS – LILA MILANO ONLUS (LILA Milano) – Italy
- FONDAZIONE VILLA MARAINI ONLUS (FVM) – Italy
- KRAJOWE CENTRUM D/S AIDS (NAC) – Poland
- Department of Health (DH-PHE) – United Kingdom
- HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH) – Croatia
- UDRUGA ZA UNAPREDENJE KVALITETE ZIVLJENJA “LET” (FLIGHT) – Croatia
- CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (IDIBAPS) – Spain
- ARCIGAY (ARCIGAY) – Italy
- ASSOCIAZIONE DELLA CROCE ROSSA ITALIANA (C.R.I.) – Italy
- KENTRO ELENCHOU & PROLIPSIS NOSIMATON (KEELPNO) – Greece
- VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS (VULSK) – Lithuania
- NACIONALINE VISUOMENES SVEIKATOS PRIEZIUROS LABORATORIJA (NVSPL) – Lithuania
- VILNIAUS PRIKLAUSOMYBES LIGU CENTRAS (VPLC) – Lithuania
- UZKRECIAMUJU LIGU IR AIDS CENTRAS (ULAC) – Lithuania
- SPITALUL CLINIC DE BOLI INFECTIOASE SI PNEUMOFTIZIOLOGIE VICTOR BABES CRAIOVA (CHIDPVB) – Romania
- INSTITUT ZA JAVNO ZDRAVLJE SRBIJE ‘MILAN JOVANOVIC – BATUT’ (IPH) – Serbia
- SLOVENSKA ZDRAVOTNICKA UNIVERZITA V BRATISLAVE (SMU) – Slovakia
- ORGANISMO AUTONOMO INSTITUTO DE SALUD PUBLICA Y LABORAL DE NAVARRA (ISPLN) – Spain
- SEMMELWEIS EGYETEM (SU) – Hungary
- INSTITUTUL DE PNEUMOFTIZIOLOGIE MARIUS NASTA (IPMN) – Romania
- HRVATSKA UDRUGA ZA BORBU PROTIV HIV-A I VIRUSNOG HEPATITISA (HUHIV) – Croatia
- ISKORAK (ISKORAK) – Croatia
- Ministry for Health – Government of Malta (MFH) – Malta